• Reliable Cell Assays with HyperFluor™ 488 Goat Anti-Mouse Ig

  2026-05-09

  Discover how HyperFluor™ 488 Goat Anti-Mouse IgG (H+L) Antibody (SKU K1204) addresses reproducibility and sensitivity challenges in cell viability and immunoassays. This scenario-driven guide offers data-backed insights for biomedical researchers seeking robust, workflow-compatible secondary antibody solutions.

• Strategic P-gp Inhibition: Zosuquidar and the Future of MDR

  2026-05-09

  Explore how Zosuquidar (LY335979) 3HCl, a potent P-gp inhibitor from APExBIO, is redefining multidrug resistance research through mechanistic precision, robust translational validation, and actionable guidance for clinical and preclinical investigators. This thought-leadership article moves beyond standard product summaries, bridging complex biological rationale, state-of-the-art workflows, and clinical implications, while integrating recent transporter-focused pharmacokinetic findings in metabolic disease.

• Verbascoside (SKU B3379): Reliable PKC/NF-κB Inhibitor for C

  2026-05-08

  This article delivers a scenario-driven, evidence-based exploration of Verbascoside (SKU B3379) for scientists tackling cell viability, proliferation, and signaling assays. Drawing on validated literature and protocol data, we demonstrate how Verbascoside supports reproducible osteoclastogenesis and PKC/NF-κB pathway research, offering practical workflow solutions and vendor selection insights.

• NMDAR Subunits Regulate Gap Junctions in TMJ Inflammatory Pa

  2026-05-07

  This study demonstrates that N-methyl-D-aspartate receptor (NMDAR) subunits GluN2A and GluN2B distinctly regulate connexin and pannexin expression in the trigeminal ganglion during temporomandibular joint (TMJ) inflammation. By dissecting the mechanistic connections between NMDAR signaling and peripheral sensitization, the findings offer new molecular targets for interventions in orofacial inflammatory allodynia.

• Light-Inducible RNA Switches Enable Precision Gene Therapy C

  2026-05-07

  A rationally designed light-inducible RNA-releasing protein (LIRP) enables optogenetic, translational-level regulation of therapeutic gene expression in vivo, offering tissue-specific and temporally controlled interventions. This technology advances the safety and flexibility of gene therapies targeting chronic metabolic and retinal diseases.

• AO/PI Double Staining Kit: Practical Guide for Cell Viabilit

  2026-05-06

  The AO/PI Double Staining Kit enables researchers to distinguish viable, apoptotic, and necrotic cells in a single assay using dual fluorescent dyes. This product is suited for rapid, reproducible cell viability, apoptosis, and necrosis detection in a range of cell biology experiments, but is not appropriate for applications requiring live-cell imaging beyond brief exposure or multiplexed staining outside AO/PI channels.

• ATRX-Deficient Glioma Sensitivity to RTK/PDGFR Inhibitors: I

  2026-05-06

  This study identifies that ATRX-deficient high-grade glioma cells are significantly more sensitive to multi-targeted receptor tyrosine kinase (RTK) and platelet-derived growth factor receptor (PDGFR) inhibitors. The findings suggest that ATRX mutation status should be considered in clinical trial design and therapeutic strategies for aggressive gliomas.

• Partial β-Secretase Inhibition Preserves Synaptic Function i

  2026-05-05

  Satir et al. (2020) demonstrate that reducing amyloid β (Aβ) production by up to 50% through partial β-secretase (BACE) inhibition does not impair synaptic transmission in primary cortical neurons. These findings support more nuanced therapeutic approaches in Alzheimer's disease, emphasizing moderate BACE inhibition to minimize adverse effects on neuronal function.

• PD0325901 MEK Inhibitor: Optimizing Cancer and Stem Cell Ass

  2026-05-05

  PD0325901, a selective MEK inhibitor supplied by APExBIO, empowers researchers to dissect RAS/RAF/MEK/ERK pathway dynamics with precision in both cancer and stem cell contexts. This guide translates recent mechanistic insights into actionable protocols, troubleshooting tips, and advanced applications for translational research.

• AT13387: Optimizing Hsp90 Inhibitor Workflows in Cancer Biol

  2026-05-04

  AT13387 stands out among Hsp90 inhibitors for its nanomolar potency, unique scaffold, and tumor-selective retention. This guide delivers actionable workflows, troubleshooting tips, and cross-domain insights to empower advanced cancer biology research with precise apoptosis and cell cycle arrest assays.

• Z-DEVD-FMK: Applied Caspase-3 Inhibitor Workflows in Apoptos

  2026-05-04

  Z-DEVD-FMK empowers researchers to dissect caspase-dependent apoptosis and neuroprotection with precision, thanks to its dual inhibition of caspase and calpain pathways. This article translates recent mechanistic insights and in vivo findings into actionable, optimized workflows for cancer and neuronal injury models.

• VX-661: Precision Rescue of F508del CFTR—Systems Biology to

  2026-05-03

  Explore VX-661, a leading F508del CFTR corrector, through the lens of systems-level protein folding and calnexin-driven rescue. This article offers advanced insights and actionable guidance for cystic fibrosis research, grounded in the latest mechanistic discoveries.

• γH2AX DNA Damage Detection Kit: Precision DSB Biomarker in A

  2026-05-02

  The γH2AX DNA Damage Detection Kit (Mouse mAb/Red) from APExBIO empowers researchers to sensitively quantify DNA double-strand breaks and repair kinetics in complex experimental systems. Its robust immunofluorescence workflow and validated antibody specificity enable high-content genotoxicity, apoptosis, and DNA repair studies, even in challenging contexts like radioimmunotherapy and nanoparticle radiosensitization.

• Targeting GOT1 for Metabolic Disruption in Pancreatic Cancer

  2026-05-02

  This study identifies ziprasidone as a novel non-competitive inhibitor of GOT1, disrupting glutamine metabolism and redox balance in pancreatic ductal adenocarcinoma (PDAC) cells. The findings provide mechanistic insight into metabolic vulnerabilities in PDAC and highlight GOT1 inhibition as a promising therapeutic strategy.

• PTX3-TLR4/NF-κB-FGF21 Axis in Glucocorticoid-Induced ONFH

  2026-05-01

  This study uncovers a protective mechanism in glucocorticoid-induced osteonecrosis of the femoral head (ONFH), identifying PTX3 as a modulator of the TLR4/NF-κB/FGF21 signaling axis. The findings reveal potential therapeutic targets and inform future osteoclastogenesis research and intervention strategies.

16264 records 1/1085 page Next 12345 下5页 Last page